United States

Rosmi Shaji

FDA staff raises no major concerns over Intercept's liver drug

Apr 05 2016

By Amrutha Penumudi and Rosmi Shaji The U.S. Food and Drug Administration's staff reviewers did not raise any major red flags over Intercept Pharmaceuticals Inc's liver drug on Tuesday, sending the stock up as much as 19 percent.

Aldeyra's eye drug effective in mid-stage trial; shares soar

Feb 29 2016

Aldeyra Therapeutics Inc said its eye drug was more effective than a placebo in treating itching and tearing associated with allergic conjunctivitis in a mid-stage study.

PTC shares sink as FDA says application does not merit review

Feb 23 2016

PTC Therapeutics Inc's shares plummeted more than 50 percent on Tuesday, after the U.S. Food and Drug Administration said the company's marketing application for a muscle disorder drug was insufficient to warrant a review.

Perrigo's adjusted profit misses for first time in five quarters

Feb 18 2016

Drugmaker Perrigo Co Plc's adjusted profit missed market estimates for the first time in five quarters as sales in its branded consumer healthcare business disappointed.

Regulus hep C combo drug effective in mid-stage study

Feb 17 2016

Regulus Therapeutics Inc said interim mid-stage data for its hepatitis C combination drug showed it had the potential to sharply reduce the duration of the treatment to four weeks from 12 weeks.

Stryker expands ambulance services with Physio-Control buy

Feb 16 2016

Medical device maker Stryker Corp said it would buy Physio-Control International Inc for $1.28 billion in cash to expand its emergency medical services business and raised its full-year earnings forecast for the second time this month.

Regeneron sees gradual adoption of cholesterol drug Praluent

Feb 09 2016

Regeneron Pharmaceuticals Inc reported lower-than-expected quarterly sales for its new cholesterol drug and reiterated expectations of a "gradual uptake" for the treatment, which has been tipped to be its next blockbuster.

Heart device maker Boston Scientific's sales miss estimates

Feb 04 2016

Heart device maker Boston Scientific Corp's quarterly revenue fell just shy of Wall Street expectations as sales in its second-biggest unit fell, sending its shares down as much as 6 percent.

Abbott Labs to buy diagnostics company Alere for $5.8 billion

Feb 01 2016

Abbott Laboratories said it would buy Alere Inc for $5.8 billion to become a leader in point-of-care testing, a fast-growing market as physicians increasingly adopt rapid tests that speed up treatment.

FDA issues Class I recall on St. Jude's defibrillator leads

Jan 22 2016

St. Jude Medical Inc said the U.S. Food and Drug Administration has issued a Class I recall on faulty parts of its devices implanted into patients to control irregular heartbeats.

World News